Atea Pharmaceuticals, Inc.
NASDAQ:AVIRBiotechnology
Healthcare
$3.99 -0.81%
-$0.04 today
- Market cap
- $320.41M
- Beta
- 0.32
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$2.14
52W Low $2.78High $6.45
Volume 0.34M
Average 0.34M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$180.89M
FY 2025 · Annual
Net Income
-$158.35M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 351.37M | 0 | 0 | 0 | 0 |
| Cost of Revenue | 167.21M | 62.39M | 70.09M | 83.37M | 0 |
| Gross Profit | 184.16M | (62.39M) | (70.09M) | (83.37M) | 0 |
| Gross Margin | 52.4% | — | — | — | — |
| Research & Development | 167.21M | 88.84M | 132.84M | 145.4M | 148.02M |
| Selling, General & Admin | 45.79M | 48.71M | 49.92M | 48.85M | 32.86M |
| Operating Expenses | 45.79M | 68.26M | 94.07M | 109.58M | 180.89M |
| Depreciation & Amortization | 29K | 260K | 416K | 416K | 416K |
| EBITDA | 138.62M | (110.84M) | (119.59M) | (131.8M) | (164.1M) |
| EBITDA Margin | 39.5% | — | — | — | — |
| Operating Income | 138.38M | (130.65M) | (164.16M) | (192.95M) | (180.89M) |
| Operating Margin | 39.4% | — | — | — | — |
| Interest Income | 213K | 11.15M | 29.22M | 25.49M | 16.38M |
| Interest Expense | 0 | 11.15M | 0 | 0 | 0 |
| Other Income / Expenses | 213K | 11.15M | 29.22M | 25.49M | 16.38M |
| Income Before Tax | 138.59M | (119.5M) | (134.94M) | (167.46M) | (164.51M) |
| Pre-Tax Margin | 39.4% | — | — | — | — |
| Income Tax Expense | 17.4M | (3.59M) | 1.02M | 925K | (6.16M) |
| Net Income | 121.19M | (115.91M) | (135.96M) | (168.39M) | (158.35M) |
| Net Margin | 34.5% | — | — | — | — |
| EPS (Basic) | 1.46 | (1.39) | (1.63) | (2.00) | (1.94) |
| EPS (Diluted) | 1.37 | (1.39) | (1.63) | (2.00) | (1.94) |
| 82.82M | 83.25M | 83.39M | 84.26M | 81.5M | |
| 88.25M | 83.25M | 83.39M | 84.26M | 81.5M |
AVIR Earnings Waterfall · TTM
NASDAQ:AVIR · Revenue to Net Income
Key Ratios
EPS$-2.11
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.8
P/S Ratio0.0
Analysis
$0 of revenue converted into -$169.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.11, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13G | SC 13G filing | Oct 6, 2026 |
How much revenue does AVIR generate?
Atea Pharmaceuticals, Inc. (AVIR) reported $0.00 of revenue in fiscal 2025.
Is AVIR profitable?
Atea Pharmaceuticals, Inc. (AVIR) reported -$158.35M of net income.
Continue the stock analysis
Jump to another research area for this company.